Claritin, Pseudoephedrine Sales Impact Schering Consumer Health Revenue
This article was originally published in The Tan Sheet
Executive Summary
Sales for the Clarinex and Claritin prescription business decreased 4% during the third quarter to $233 mil., Schering-Plough Executive VP - Global Pharmaceuticals President Carrie Cox stated in an Oct. 24 third-quarter earnings call